Two dangerous viral diseases that are simultaneously in the news in 2026 share a biological trap: in their earliest, most treatable days, they can look exactly like the flu. Clinical reviews published June 22, 2026 in the Canadian Medical Association Journal provide updated guidance for clinicians on recognizing and managing both Bundibugyo Ebola virus disease and hantavirus pulmonary syndrome, with explicit attention to the diagnostic challenge posed by their non-specific early presentations.
"Both Ebola and hantavirus can start with very mild symptoms that resemble the flu, but the window for effective intervention can close quickly if not recognized early," the CMAJ guidance summarizes, as widely reported by SciTechDaily.
The timing of this clinical education is not coincidental. The DRC Bundibugyo Ebola outbreak has now exceeded 2,344 confirmed cases and 930 deaths, the fastest-growing Ebola epidemic on record. A separate cluster of Andes hantavirus infections linked to a cruise ship in the Atlantic prompted a CDC Health Alert Network advisory to U.S. clinicians in June. Two U.S. citizens have been medically evacuated with confirmed Bundibugyo infection. The risk to most Americans remains low, but the risk to clinicians of missing these diseases in a returning traveler or an exposed patient is real.
Why This Matters
In medicine, the window between "sick enough to be recognized too sick to recover" can be measured in hours for both diseases. Ebola's case fatality rate for Bundibugyo ranges from 30% to 50%. Hantavirus pulmonary syndrome kills approximately 35% of people who develop it in the United States, according to the CDC. Both diseases are overwhelmingly more survivable when caught early in the non-specific symptomatic phase rather than when they have progressed to their characteristic, unmistakable, and often irreversible severe presentations.
The clinical challenge is that the early phase is indistinguishable from a dozen less dangerous illnesses without context: specifically, without asking about travel history and exposure history. A patient who has not traveled to DRC and has no rodent exposure almost certainly does not have Ebola or hantavirus. A patient who has traveled to Ituri Province in the past 21 days, or who has cleaned a rodent-infested structure recently, with a fever and myalgia, is a different clinical situation entirely.
What the CMAJ Reviews Found
Two brief review articles, both published in the same June 22, 2026 issue of CMAJ, provide updated clinical summaries:
"Ebola Virus Disease" by Maxime J. Billick, William K. Silverstein, and Isaac I. Bogoch (doi: 10.1503/cmaj.260834) states that typical Ebola symptoms include fever of 38°C or higher, fatigue, muscle pain, and gastrointestinal problems including nausea, vomiting, and diarrhea. Despite Ebola's association with hemorrhagic disease, the review notes that fewer than half of patients develop hemorrhagic symptoms. The incubation period ranges from 2 to 21 days. Diagnosis is confirmed by PCR testing. The review states that people who develop symptoms and have possible exposure risks should be evaluated and tested, including travelers who have recently visited countries with active Ebola outbreaks.
"Hantavirus" by Marie-Laure Oberweis, Ana C. Blanchard, and Esther Vaugon (doi: 10.1503/cmaj.260789) notes that early hantavirus symptoms can include fever, fatigue, and muscle aches, especially in large muscle groups like the thighs, hips, back, and shoulders. Early symptoms such as fever, headache, muscle aches, nausea, and fatigue can be easily confused with influenza or other viral illnesses, the review states. Hantavirus diagnosis relies on serological assays and PCR testing conducted by specialized laboratories. There are no approved antiviral therapies or vaccines; management centers on supportive care.
The reviews emphasize that both diseases require clinicians to specifically ask about exposure history, as physical examination and initial laboratory work cannot distinguish early Ebola or hantavirus from common respiratory or gastrointestinal illnesses.
The Two Specific Threats Now Active in 2026
Bundibugyo Ebola in DRC: The CDC issued a HAN Health Advisory on May 19, 2026 alerting U.S. clinicians to the DRC outbreak and providing recommendations for testing and biosafety when evaluating patients with potential exposure, according to the CDC HAN advisory. The CDC has elevated its DRC travel notice and now recommends avoiding non-essential travel to Haut-Uele, Ituri, North Kivu, and Tshopo provinces. Anyone who has been in those provinces in the past 21 days and develops fever should be evaluated urgently and inform their clinician.
Andes Hantavirus Cruise Ship Cluster: A May 2026 cluster of severe acute respiratory illness among passengers and crew of a cruise ship in the Atlantic was identified as Andes virus hantavirus, prompting a CDC HAN advisory for U.S. clinicians on June 2, 2026. Andes virus is the only hantavirus strain known to spread person to person, though this is rare and requires close, prolonged contact. The CDC advised clinicians to be aware of potential imported cases and to use stringent infection control, including airborne, droplet, and contact precautions, for suspected hantavirus cases.
In the U.S., the more commonly encountered hantavirus is Sin Nombre virus, transmitted by deer mice and linked to hantavirus pulmonary syndrome cases primarily in the Western United States. An average of 30 to 40 U.S. cases occur annually, with the highest rates in New Mexico, Colorado, Arizona, and California.
Where the Risk Is Highest
For Ebola: The risk remains highly concentrated in people who have traveled to DRC's affected provinces (Ituri, North Kivu, Haut-Uele, Tshopo) in the past 21 days. Two U.S. citizens have been infected, both humanitarian workers in DRC who were medically evacuated to Germany. There are no DRC-related cases on U.S. soil.
For domestic hantavirus (Sin Nombre): Risk is highest in people who have had rodent exposure in the western U.S., including cleaning rodent-infested structures, camping in areas with heavy rodent activity, or disturbing areas where rodent droppings or nests are present. The summer months are peak exposure season as people spend more time outdoors and clean out spaces where rodents may have wintered.
What Doctors and Experts Say
The CMAJ review authors summarize the core clinical message succinctly: when a patient presents with fever, fatigue, myalgia, and other non-specific symptoms, the key to distinguishing a common illness from a potential hemorrhagic fever or hantavirus infection is the exposure history. No amount of physical examination or routine laboratory work will make that distinction.
The CDC's guidance in its Ebola HAN advisory instructs clinicians to consider Ebola in anyone with compatible symptoms who has traveled to an affected country or had contact with a confirmed or suspected Ebola patient within the past 21 days, and to contact their state or local health department immediately before performing any diagnostic procedures.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Source of CMAJ clinical reviews: Canadian Medical Association Journal, Volume 198, Issue 24, June 22, 2026 (Ebola doi: 10.1503/cmaj.260834; Hantavirus doi: 10.1503/cmaj.260789)
- Primary authors: Billick, Silverstein, and Bogoch (Ebola); Oberweis, Blanchard, and Vaugon (Hantavirus)
- Brief's characterization of "CDC guidance" note: These are CMAJ clinical reviews that draw on CDC and WHO guidance; the CDC issued separate HAN advisories for Ebola (HAN 530, May 2026) and hantavirus (HAN 528, June 2026)
- Bundibugyo Ebola case fatality rate: 30% to 50% in current outbreak
- Hantavirus pulmonary syndrome (Sin Nombre) case fatality rate: Approximately 35% in the U.S. (CDC)
- Key diagnostic point: Neither disease can be distinguished from flu in its early days by clinical examination alone; exposure history is the critical discriminator
- Andes hantavirus: The only hantavirus with documented person-to-person spread, though rare and requiring close contact
- What readers should know: If you have recently traveled to DRC or had rodent exposure in the western U.S. and develop fever with muscle aches, contact a health care provider immediately and be specific about your travel and exposure history
Who Should Pay Attention?
- Clinicians in the U.S. who may evaluate patients returning from DRC or who may see hantavirus cases during summer outdoor season
- Travelers returning from DRC in the past 21 days, particularly from the four affected provinces
- Humanitarian and aid workers returning from DRC or deploying there
- People in the western U.S. who have recently cleaned rodent-infested spaces, camped in rodent-endemic areas, or had other potential hantavirus exposure
Symptoms and the Critical Exposure Questions
Both Ebola and hantavirus may initially present with:
- Fever (often above 38°C / 100.4°F)
- Severe fatigue
- Muscle aches (myalgia), especially large muscle groups
- Headache
- Nausea and vomiting
- Diarrhea
Distinctive progression signs:
For Ebola: Symptoms progress to severe gastrointestinal illness, and in some cases hemorrhagic manifestations. Incubation is 2 to 21 days after exposure.
For hantavirus (HPS): After initial flu-like phase, rapid progression to shortness of breath, low oxygen levels, and pulmonary edema (fluid in the lungs), which can be fatal within hours. Incubation for Sin Nombre hantavirus is typically 1 to 8 weeks after exposure.
Critical exposure questions to answer:
- Have you traveled to DRC or the affected provinces in the past 21 days?
- Have you had contact with someone diagnosed with or suspected of having Ebola?
- Have you cleaned, swept, or disturbed areas where rodent droppings or nests were present?
- Have you camped, worked, or lived in areas with heavy rodent activity?
A positive answer to any of these questions, combined with fever and flu-like symptoms, warrants immediate medical evaluation.
What You Can Do Now
- If you have recently traveled to DRC's affected provinces and develop fever or flu-like symptoms, call your health care provider before visiting in person. Tell them specifically where you traveled and when.
- If you have had recent rodent exposure in the western U.S. and develop fever, muscle aches, and respiratory symptoms, contact a health care provider immediately and disclose the exposure.
- Clinicians: Review the CDC's HAN advisories for Ebola (HAN 530) and hantavirus (HAN 528) for current testing protocols and biosafety guidance. Both are available at cdc.gov/han .
- People planning summer activities in rodent-endemic western U.S. areas should take standard hantavirus prevention precautions: seal rodent entry points, use PPE when cleaning potential rodent-contaminated spaces, and avoid sweeping or vacuuming areas with visible droppings.
Cost and Access: What Patients Should Know
Suspected Ebola evaluation is coordinated through state health departments and designated biocontainment centers; patients should not arrive at a standard emergency room without calling ahead. Hantavirus testing is performed through state laboratories and requires physician coordination. For both diseases, emergency evaluation and testing are covered by insurance, Medicare, and Medicaid.
What Happens Next
The DRC Bundibugyo outbreak continues to evolve, and any new U.S. cases would trigger immediate clinical alerts through the CDC HAN system. MedicalDaily will report on significant developments in either the DRC outbreak or the Andes hantavirus cruise ship cluster.
The Bottom Line
Two dangerous viral diseases are simultaneously circulating at unusual levels in 2026: Bundibugyo Ebola in DRC (930-plus deaths) and a novel Andes hantavirus cluster linked to a cruise ship. Both begin with the same flu-like symptoms that clinicians see dozens of times a day. The only thing that distinguishes them from ordinary illness in the first critical days is the exposure history. Ask about travel to DRC. Ask about rodent exposure. Act before the window closes.
